Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 11 of 11 publications.

Meyers J, Hoog M, Mody R, Yu M, Davis K. The health care resource utilization and costs among patients with type 2 diabetes and either cardiovascular disease or cardiovascular risk factors an analysis of a US health insurance database. Clin Ther. 2021 Nov;43(11):1827-42. doi: 10.1016/j.clinthera.2021.09.003

Meyers J, Sinha A, Samant S, Candrilli S. The economic burden of congenital cytomegalovirus disease in the first year of life: a retrospective analysis of health insurance claims data in the United States. Clin Ther. 2019 Jun;41(6):1040-1056. doi: 10.1016/j.clinthera.2019.04.022

Maiese EM, Ainsworth C, Le Moine JG, Ahdesmaki O, Bell J, Hawe E. In reply: Network meta-analyses are not about a single treatment but about sets of regimens. Clin Ther. 2019 Jan;41(1):188-90. doi: 10.1016/j.clinthera.2018.11.011

Maiese EM, Ainsworth C, Le Moine JG, Ahdesmaki O, Bell J, Hawe E. Comparative efficacy of treatments for previously treated multiple myeloma: a systematic literature review and network meta-analysis. Clin Ther. 2018 Mar;40(3):480-94. doi: 10.1016/j.clinthera.2018.01.014

Earnshaw SR, McDade CL, Chu Y, Fleige LE, Sievenpiper JL. Cost-effectiveness of maintaining daily intake of oat β-glucan for coronary heart disease primary prevention. Clin Ther. 2017 Apr;39(4):804-818.e. doi: 10.1016/j.clinthera.2017.02.012

Mladsi D, Ronquest N, Odom D, Miles L, Saag K. Cost-effectiveness of low-dose submicron diclofenac compared with generic diclofenac. Clin Ther. 2016 Nov;38(11):2418-29. doi: 10.1016/j.clinthera.2016.09.013

Graham CN, Maglinte GA, Schwartzberg LS, Price TJ, Knox HN, Hechmati G, Hjelmgren J, Barber B, Fakih MG. Economic analysis of panitumumab compared with cetuximab in patients with wild-type KRAS metastatic colorectal cancer that progressed after standard chemotherapy. Clin Ther. 2016 Jun;38(6):1376-91. doi: 10.1016/j.clinthera.2016.03.023

Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C, Charbonneau C, Weinstein D, Kantecki M, Schlamm H, Maertens J. Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients. Clin Ther. 2015 Jun 1;37(6):1317-28. doi: 10.1016/j.clinthera.2015.03.021

Earnshaw SR, McDade C, Chapman AM, Jackson D, Schwamm L. Economic impact of using additional diagnostic tests to better select patients with stroke for intravenous thrombolysis in the United Kingdom. Clin Ther. 2012 Jul 1;34(7):1544-58.

Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther. 2009 Jan 1;31(1):194-212.

Earnshaw SR, Moride Y, Rochon S. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clin Ther. 2007 Sep 1;29(9):2096-106.